Home » Management » Risk Management
Guideline on Risk Management Systems for Medicinal Products for ...
Source: www.emea.europa.eu
Topic: Risk Management
Sort Desciption: A risk management system is defined in this guideline as a set of ... The guideline also describes how such a risk management system can be ...
Content Inside: European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus Canary Wharf London E14 4HB UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea.eu.int http://www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged London 14 November 2005 Doc. Ref. EMEA/CHMP/96268/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON RISK MANAGEMENT SYSTEMS FOR MEDICINAL PRODUCTS FOR HUMAN USE DRAFT AGREED BY PhVWP 26 July 2005 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION 27 July 2005 END OF CONSULTATION (DEADLINE FOR COMMENTS) 5 October 2005 ADOPTION BY CHMP 14 November 2005 DATE FOR COMING INTO EFFECT 20 November 2005 THIS GUIDELINE WILL BE INCLUDED AS CHAPTER I.3 OF VOLUME 9 EMEA/CHMP/96268/2005 Page 2/32 EMEA 2005 GUIDELINE ON RISK MANAGEMENT SYSTEMS FOR MEDICINAL PRODUCTS FOR HUMAN USE 1. INTRODUCTION (background) 4 2. SCOPE 5 3. LEGAL BASIS 5 4. RISK MANAGEMENT DESCRIPTION AND THE REQUIREMENTS FOR APPLICANTS AND MARKETING AUTHORISATION HOLDERS 6 4.1 Description of the risk management system. 6 4.2 EU Risk Management Plan (EU-RMP) 7 4.3 Situations when an EU-RMP is required 7 4.3.1 Authorisations via the centralised procedure 8 4.3.2 Authorisations via the mutual recognition or decentralised procedure. 8 4.4 Location in the dossier 8 4.5 Safety Specification 8 4.5.1 Non-clinical 9 4.5.2 Clinical 9 4.5.2.1 Limitations of the human safety database 9 4.5.2.2 Populations not studied in the pre-authorisation phase 10 4.5.2.3 Adverse Events/Adverse Reactions 10 4.5.2.4 Identified and potential interactions including food-drug and drug-drug interactions 12 4.5.2.5 Epidemiology 12 4.5.2.6 Pharmacological class effects 12 4.5.2.7 Additional EU requirements 12 4.5.3 Summary 13 4.6 Pharmacovigilance Plan 13 4.6.1 Routine Pharmacovigilance 13 4.6.2 Additional ...
guideline risk management systems medicinal, eu rmp, eu rmp guideline, guideline on risk management systems for medicinal products for human use, medicinal product risk management plan, chmp and risk manadement, chmp guideline on risk management systems for medicinal products for human use, rmp emea, risk management plan for medicinal products, emea guidance risk management plan, emea risk management program, risk management of medicinal products, pharmacovigilance specification, writting a risk management plan for medicinal products, emea chmp 96268 2005, risk management plan guideline emea, chmp rmp, risk management program medicinal products, pharmacovigilance specification and risk management plan, safety evaluation pre authorisation phase
Related PDF Files:
» Risk Management Guidelines for Commercial Banks & DFIs.
Host: www.sbp.org.pk
» Enterprise Risk Management Integrated Framework
Host: www.coso.org
Search
Categories
Latest Download
- A Guide To Business Report Writing
- Strategic Marketing Plan 2010
- Risk Management Guidelines For Commercial Banks & Dfis.
- Penn Economic History Forum 2005 - 2006
- Overview Of Career Development Theory
- Customer Service Guide
- Customer Service Case Studies How To Deal With Difficult Customer ...
- Strategy Consulting Marketplace 2006-2009: Strategy Consulting ...
- Sam Walton's Formula For Wal-mart
- Project Management Guide